Login to Your Account

BMS looks to 'marry' adaptive, innate immunity with $2.32B+ IFM buy

By Marie Powers
News Editor

Friday, August 4, 2017

Two-year-old IFM Therapeutics Inc. became the latest biopharma unicorn, as Bristol-Myers Squibb Co. picked up the Boston-based company for $300 million up front and another $1.01 billion in potential milestones.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription